Reaction
Nail Psoriasis reporting signals
As of the last recalculation, Nail Psoriasis appears in 610 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is SECUKINUMAB (PRR 53.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Secukinumab | 179 | 53.2 | 53.2 |
| Risankizumab-Rzaa | 60 | 27.7 | 27.7 |
| Ixekizumab | 16 | 15.1 | 15.1 |
| Guselkumab | 12 | 11.7 | 11.7 |
| Apremilast | 18 | 4.3 | 4.3 |